Vinge acted for Xspray Pharma in connection with its rights issue of units. Through the rights issue of units, Xspray (STO:XSPRAY) is expected to receive approximately SEK 300...
You must be a Standard 1 Year member to access this content.
Vinge advised Biotage AB on the deal. Global investment firm KKR’s life science platform Gamma Biosciences has sold Astrea Bioseparations, a company focused on helping to bring small...
You must be a Standard 1 Year member to access this content.
Vinge advised Immunovia on the deal. Immunovia AB (publ) has resolved on a new issue of shares of approximately SEK 202.2 million with preferential right for...
You must be a Standard 1 Year member to access this content.
Vinge has advised Egetis Therapeutics AB on the deal. Egetis Therapeutics AB (publ), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization...
You must be a Standard 1 Year member to access this content.
Vinge has advised Hansa Biopharma on the deal. Hansa Biopharma announced directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs....
You must be a Standard 1 Year member to access this content.
Vinge has advised Oncopeptides on the deal. Wigge & Partners advised the European Investment Bank (EIB). The loan agreement with the European Investment Bank (EIB) grants...
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised Nordea and Pareto on the deal. Vinge has advised Re:NewCell. Re:NewCell AB (publ) has carried out a primary issuance of shares of approximately...
You must be a Standard 1 Year member to access this content.
Vinge has advised Xspray Pharma on the deal. Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 100. The Issue is expected...
You must be a Standard 1 Year member to access this content.
Vinge advised Vimian on the deal. Vimian completed a directed share issue of approximately MSEK 1,500, before issue costs. The share issue is in part based on...
You must be a Standard 1 Year member to access this content.
Vinge advised Oncopeptides on the deal. The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds...
You must be a Standard 1 Year member to access this content.
Setterwalls has advised Trill Impact on the deal. Vinge advised Cinclus Pharma. Cinclus Pharma Holding AB, a biopharmaceutical company focused on the development of a novel...
You must be a Standard 1 Year member to access this content.
Vinge has advised ABG Sundal Collier and Carnegie on the deal. ABG Sundal Collier and Carnegie partecipated in a capital raising in Xshore of approximately SEK 500 million...
You must be a Standard 1 Year member to access this content.
